GLP1R and type 2 diabetes mellitus: Our network meta-analysis showed that 1) there was no evidence to indicate an increased risk of fracture associated with DPP-4i–, GLP-1 RA–, and SGLT-2i–based therapies in patients with T2DM compared with other antidiabetic agents or placebo; 2) secondary outcomes based on fracture of different parts indicated that DPP-4i, GLP-1 RAs, and SGLT-2i did not increase the risk of fracture, respectively.